Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
Healthy Volunteers
NCT06912048

Understanding Individual Variability in Neuronal Signal Transmission to Target Organs in Health and Disease

Led by University of Ulm · Updated on 2025-07-10

52

Participants Needed

1

Research Sites

102 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to evaluate the influence of parasympathetic transmission from the brain to different metabolic organs. This transmission can be blocked with the muscarinic antagonist atropine. Participants will undergo an oral glucose tolerance test combined with a double tracer dilution technique either with atropine infusion or placebo. Healthy individuals and high-risk individuals will be compared to identify possible changes in signaling in high-risk groups. In addition, men and women will be included to take into account possible sex differences.

CONDITIONS

Official Title

Understanding Individual Variability in Neuronal Signal Transmission to Target Organs in Health and Disease

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age at least 18 years
  • Body mass index (BMI) between 20 and 24.9 kg/m2 for healthy groups or more than 28 kg/m2 for overweight groups
  • For women, use of hormonal contraception with a single-phase preparation (e.g., Nuvaring)
  • Ability to understand and voluntarily sign an informed consent form before study exams
Not Eligible

You will not qualify if you...

  • Drug or alcohol abuse
  • Smoking
  • Use of medications affecting blood sugar or central/autonomic nervous system, such as anti-epileptics, beta blockers, dopamine agonists, antidepressants, or antihistamines
  • Pre-existing cardiac conditions or known cardiac arrhythmia
  • Neurological pre-existing conditions
  • Known allergies to study ingredients like paracetamol or atropine
  • Known narrow-angle glaucoma
  • Known hyperthyroidism
  • Known urinary tract or prostate diseases
  • Pregnancy or breastfeeding
  • At screening, hemoglobin below 12 g/dl for women or below 14 g/dl for men
  • No consent to be informed about incidental pathological findings
  • Any clinical condition judged by a physician to endanger safety or study success
  • Liver dysfunction
  • Renal insufficiency

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Ulm University Hospital

Ulm, Germany, 89081

Actively Recruiting

Loading map...

Research Team

M

Martin Heni, MD

CONTACT

A

Andrea Geissler

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

BASIC_SCIENCE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Understanding Individual Variability in Neuronal Signal Transmission to Target Organs in Health and Disease | DecenTrialz